Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleA questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
Author(s)Notcutt WG.
Journal, Volume, IssuePrim Health Care Res Dev. 2012 Jul 12:1-8.
Major outcome(s)Most respondents experienced improvements across a range of symptoms.
IndicationMultiple sclerosis;Pain;SpasticityAbstract
MedicationCannabis

Aim To identify the areas of daily function most affected by the introduction of
Sativex, a cannabis-based medicine, and the impact on caregivers and people with
multiple sclerosis (MS). BACKGROUND: Cannabinoid medicines have recently become
available on prescription in several parts of the world, principally for the
treatment of spasticity in people with MS. Their efficacy and safety have been
demonstrated in the setting of randomised controlled clinical trials. Results of
such studies may not always reflect the wider effectiveness that a medicine shows
when used in clinical practice. METHODS: A short questionnaire survey consisting
mostly of multiple-choice questions, along with some free-text questions aimed at
the patient and primary caregiver (ie, partner, mother, nurse or outside carer).
The questionnaire was developed in consultation with a patient representative
organisation, field tested, ethics approval gained, then distributed to
prescribers in the United Kingdom, with the request that they in turn forward it
to any patients who had received repeat prescriptions for Sativex within the
previous 16 weeks. Patients were seen in both a primary care (general practice)
and a secondary care (hospital) setting. There was no control group in this
study. Most patients had MS, and the primary reasons for using Sativex were
spasticity and pain. Findings The response rate was 57%, with 124 questionnaires
returned. The majority of respondents and their caregivers reported improvements
across a range of daily functional activities, alongside a reduction in the use
of concomitant anti-spasticity medication and in the use of other healthcare
resources.

Route(s)Sublingual
Dose(s)
Duration (days)
Participants124 patients receiving Sativex in different medical conditio
DesignSurvey
Type of publicationMedical journal
Address of author(s)Consultant Anaesthetist, Pain Research Unit, James Paget University Hospital, Great Yarmouth, Norfolk, UK.
Full text

[Back to Overview]  [IACM Homepage]


up